Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
CP-724,714, a potent and selective orally active HER2 tyrosine kinase inhibitor, was discontinued from clinical development due to unexpected hepatotoxicity in cancer patients. Based on the clinical manifestation of the toxicity, CP-724,714 likely exerted its hepatotoxicity via both hepatocellular injury and hepatobiliary cholestatic mechanisms. The direct cytotoxic effect, hepatobiliary disposition of CP-724,714, and its inhibition of active canalicular transport of bile constituents were evaluated in established human hepatocyte models and in vitro transporter systems. CP-724,714 exhibited direct cytotoxicity using human hepatocyte imaging assay technology with mitochondria identified as a candidate organelle for its off-target toxicity. Additionally, CP-724,714 was rapidly taken up into human hepatocytes, partially via an active transport process, with an uptake clearance approximately fourfold higher than efflux clearance. The major human hepatic uptake transporter, OATP1B1, and efflux transporters, multidrug resistance protein 1 (MDR1) and breast cancer resistance protein, were involved in hepatobiliary clearance of CP-724,714. Furthermore, CP-724,714 displayed a concentration-dependent inhibition of cholyl-lysyl fluorescein and taurocholate (TC) efflux into canaliculi in cryopreserved and fresh cultured human hepatocytes, respectively. Likewise, CP-724,714 inhibited TC transport in membrane vesicles expressing human bile salt export pump with an IC(50) of 16 microM. Finally, CP-724,714 inhibited the major efflux transporter in bile canaliculi, MDR1, with an IC(50) of approximately 28 microM. These results suggest that inhibition of hepatic efflux transporters contributed to hepatic accumulation of drug and bile constituents leading to hepatocellular injury and hepatobiliary cholestasis. This study provides likely explanations for clinically observed adverse liver effects of CP-724,714.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Considering that mechanisms leading to alterations in bile-acid homeostasis are believed in part to be responsible for recent prominent late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017)”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Feng et al. 2009
Citations
Cites
Büchler, M., König, J., Brom, M., Kartenbeck, J., Spring, H., Horie, T., & Keppler, D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15091 · Cited by 638
Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6
Cui, Y., König, J., Leier, I., Buchholz, U., & Keppler, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004968200 · Cited by 515
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496
Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury
Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., & de Graaf, D. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn109 · Cited by 492
Self-citationFeng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Self-citationJansen, P. L. M., Strautnieks, S. S., Jacquemin, E., Hadchouel, M., Sokal, E. M., Hooiveld, G. J. E. J., Koning, J. H., de Jager-Krikken, A., Kuipers, F., Stellaard, F., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70287-8 · Cited by 433
Byrne, J. A., Strautnieks, S. S., Mieli–Vergani, G., Higgins, C. F., Linton, K. J., & Thompson, R. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36591 · Cited by 337
Hepatobiliary transporters and drug‐induced cholestasis†
Pauli‐Magnus, C., & Meier, P. J. (2006) · Hepatology · doi:10.1002/hep.21359 · Cited by 285
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256
Correlation of Biliary Excretion in Sandwich-Cultured Rat Hepatocytes and In Vivo in Rats
Liu, X., Chism, J. P., LeCluyse, E. L., Brouwer, K. R., & Brouwer, K. L. R. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15299-3 · Cited by 228
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationSwift*, B., Pfeifer*, N. D., & Brouwer, K. L. R. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491881 · Cited by 365
Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Lightfoot-Dunn, R., & Hamadeh, H. K. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq269 · Cited by 325
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“…responsible for recent prominent late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017), there is an increasing need and…”
BackgroundObaidat, A., Roth, M., & Hagenbuch, B. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100556 · Cited by 295
Stieger, B. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_5 · Cited by 269
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Shah, R. R., Morganroth, J., & Shah, D. R. (2013) · Drug Safety · doi:10.1007/s40264-013-0048-4 · Cited by 252
Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243
Human ABCG2: structure, function, and its role in multidrug resistance.
Mo, W., & Zhang, J. (2012) · PubMed · Cited by 305
Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., & Will, Y. (2014) · Hepatology · doi:10.1002/hep.27206 · Cited by 215
“There are many physiological reasons outlined in the introduction to suspect that drugs that are dual and potent BSEP and mitochondrial inhibitors may play an important role in the manifestation of clinical DILI such as: 1) BSEP is an ATP-dependent transport protein; 2) hepatobiliary transporter activity (BSEP and MRP…”
BackgroundShah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., & Aleo, M. D. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv152 · Cited by 148
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 151
Buxhofer‐Ausch, V., Secky, L., Wlcek, K., Svoboda, M., Kounnis, V., Briasoulis, E. C., Tzakos, A. G., Jaeger, W., & Thalhammer, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/863539 · Cited by 125
Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity
Castellino, S., O'Mara, M., Koch, K. M., Borts, D. J., Bowers, G. D., & MacLauchlin, C. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040949 · Cited by 106
Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy
Thakkar, N., Lockhart, A. C., & Lee, W. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9740-x · Cited by 112
Hill, A., Mesens, N., Steemans, M., Xu, J. J., & Aleo, M. D. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.645578 · Cited by 111
Self-citationEffects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria
Zhang, J., Salminen, A. T., Yang, X., Luo, Y., Wu, Q., White, M. C., Greenhaw, J. J., Ren, L., Bryant, M., Salminen, W. F., et al. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1918-1 · Cited by 104
Paech, F., Bouitbir, J., & Krähenbühl, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00367 · Cited by 106
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
Woodhead, J. L., Yang, K., Siler, S. Q., Watkins, P. B., Brouwer, K. L. R., Barton, H. A., & Howell, B. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00240 · Cited by 93
Deo, A. K., Prasad, B., Balogh, L. M., Lai, Y., & Unadkat, J. D. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.043810 · Cited by 90
Cook, J., Feng, B., Fenner, K. S., Kempshall, S., Liu, R., Rotter, C. J., Smith, D. A., Troutman, M. D., Ullah, M., & Lee, C. A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900174z · Cited by 61
Self-citationBSEP inhibition – In vitro screens to assess cholestatic potential of drugs
Kis, E., Ioja, E., Rajnai, Z., Jani, M., Méhn, D., Herédi‐Szabó, K., & Krajcsi, P. (2011) · Toxicology in Vitro · doi:10.1016/j.tiv.2011.11.002 · Cited by 64
Aleo, M. D., Shah, F., Allen, S. W., Barton, H. A., Costales, C., Lazzaro, S., Leung, L. Y., Nilson, A. L., Obach, R. S., Rodrigues, A. D., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00262 · Cited by 58
Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
Jackson, K. D., Durandis, R., & Vergne, M. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082367 · Cited by 60
High-content screening technology for studying drug-induced hepatotoxicity in cell models
Tolosa, L., Gómez‐Lechón, M. J., & Donato, M. T. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1503-z · Cited by 64
Slizgi, J. R., Lu, Y., Brouwer, K. R., St. Claire, R. L., Freeman, K. M., Pan, M., Brock, W. J., & Brouwer, K. L. R. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv231 · Cited by 53
The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury
Amacher, D. E. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.658041 · Cited by 55
Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity
Zhao, Q., Zhang, T., Xiao, X., Huang, J., Wang, Y., Gonzalez, F. J., & Li, F. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14664 · Cited by 51
Crowe, A., Zheng, W., Miller, J. L., Pahwa, S., Alam, K., Fung, K., Rubin, E., Yin, F., Ding, K., & Yue, W. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2634-3 · Cited by 49
Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors
Khurana, V., Minocha, M., Pal, D., & Mitra, A. K. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2013-0062 · Cited by 51
Organic anion-transporting polypeptides: a novel approach for cancer therapy
Liu, T., & Li, Q. (2013) · Journal of drug targeting · doi:10.3109/1061186x.2013.832767 · Cited by 44
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
Viganò, M., Milia, M. L., Grassini, M. V., Pugliese, N., Giorgio, M. D., & FAGIUOLI, S. (2023) · Cancers · doi:10.3390/cancers15061766 · Cited by 44
Spraggs, C. F., Xu, C., & Hunt, C. M. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.24 · Cited by 41
Giri, S., Nieber, K., & Bader, A. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003792521 · Cited by 36
Primary hepatocyte cultures as prominentin vitrotools to study hepatic drug transporters
Ramboer, E., Vanhaecke, T., Rogiers, V., & Vinken, M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.756010 · Cited by 34
P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2
Eno, M. R., Elgendy, B., & Cameron, M. D. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00524 · Cited by 29
Lu, X., Liu, L., Shan, W., Kong, L., Chen, N., Lou, Y., & Zeng, S. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190426152830 · Cited by 31
Membrane Vesicle ABC Transporter Assays for Drug Safety Assessment
van Staden, C. J., Morgan, R. E., Ramachandran, B., Chen, Y., Lee, P. H., & Hamadeh, H. K. (2012) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx2305s54 · Cited by 25
Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging
Tang, L., Peng, C., Tang, B., Li, Z., Wang, X., Li, J., Gao, F., Huang, L., Xu, D., Zhang, P., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.205088 · Cited by 20
Obach, R. S., LaChapelle, E., Brodney, M. A., Vanase-Frawley, M. A., Kauffman, G. W., & Sawant‐Basak, A. (2016) · Xenobiotica · doi:10.3109/00498254.2016.1152522 · Cited by 19
Donato, M. T., Gómez-Lechón, M. J., & Tolosa, L. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1271784 · Cited by 20
Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors
Shi, Q., Yang, X., Ren, L., & Mattes, W. B. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1727886 · Cited by 18
Ryan, J., Morgan, R. E., Chen, Y., Volak, L. P., Dunn, R. T., & Dunn, K. W. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079277 · Cited by 18
Xu, J. J., Dunn, M. C., Smith, A. R., & Tien, E. S. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-337-0_6 · Cited by 14
Self-citationJain, S., & Ecker, G. F. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9420-5_26 · Cited by 16
Lapham, K., Novak, J. J., Marroquin, L. D., Swiss, R. L., Qin, S., Strock, C. J., Scialis, R. J., Aleo, M. D., Schroeter, T., Eng, H. F., et al. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00262 · Cited by 12
Drug–Drug Interactions: Designing Development Programs and Appropriate Product Labeling
Hutzler, J. M., Cook, J., & Fleishaker, J. C. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7937-7_2 · Cited by 13
Qiu, L., Finley, J. E., Taimi, M., Aleo, M. D., Strock, C., Gilbert, J., Qin, S., & Will, Y. (2015) · Applied In Vitro Toxicology · doi:10.1089/aivt.2015.0014 · Cited by 12
Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy
Liu, H., Zhu, Y., Chi, Y., Zhang, Y., Li, X., Wen, W., Shan, L., Wang, Y., & Dai, B. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107653 · Cited by 12
In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk
Norona, L. M., Fullerton, A. M., Lawson, C., Leung, L., Brumm, J., Kiyota, T., Maher, J. M., Khojasteh, C., & Proctor, W. R. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02804-4 · Cited by 12
Suzuki, Y., Nakagawa, S., Endo, T., Sotome, A., Yuan, R., Asano, T., Otsuguro, S., Maenaka, K., Iwasaki, N., & Kadoya, K. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01310-y · Cited by 10
Niu, C., Xie, X., Liu, R., Liang, X., Hu, Y., & Lai, Y. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.124.001675 · Cited by 8
Kalgutkar, A. S. S., Chen, D., Varma, M. V. S., Feng, B., Terra, S. G., Scialis, R. J., Rotter, C. J., Frederick, K. S., West, M. A., Goosen, T. C., et al. (2013) · Xenobiotica · doi:10.3109/00498254.2013.791004 · Cited by 7
Self-citationUnderstanding the clinical pharmacokinetics of a GABAApartial agonist by application ofin vitrotools
Sawant, A. D., Miller, E. L., Duignan, D. B., Brodfuehrer, J., Winter, S. M., Nelson, F. R., Kamel, A. M., Obach, R. S., & Vaz, A. D. N. (2010) · Xenobiotica · doi:10.3109/00498254.2010.481057 · Cited by 6
Self-citationThe bile salt export pump (BSEP/ABCB11)
Lai, Y. (2013) · Elsevier eBooks · doi:10.1533/9781908818287.327 · Cited by 8
Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer
Martinello, R., Milani, A., Geuna, E., Zucchini, G., Aversa, C., Nuzzo, A., & Montemurro, F. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1153063 · Cited by 5
Dong, L., Meng, F., Wu, L., Mitchell, A. V., Block, C. J., Zhang, B., Craig, D. B., Jang, H., Chen, W., Yang, Q., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4108 · Cited by 4
Qiu, Y.-Q., Zhou, J., Kang, X.-S., Shen-Tu, J.-Z., Ding, L.-M., Tan, F.-L., Guo, J., & Li, L.-J. (2012) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.4314/ajtcam.v9i3.20 · Cited by 4
Inoue, K., Kikuchi, K., Takahashi, K., Hitaoka, S., Kusano, K., & Komori, T. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000995 · Cited by 4
Organic anion-transporting polypeptides (OATPs/SLCOs)
Lai, Y. (2013) · Elsevier eBooks · doi:10.1533/9781908818287.353 · Cited by 4
Crowe, A., Miller, J. L., & Yue, W. (2019) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3343 · Cited by 1
Inoue, K., Kakiki, M., & Komori, T. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100164 · Cited by 1
Çetin, B., Bilgetekin, İ., Cengiz, M., & Özet, A. (2017) · Drugs & Therapy Perspectives · doi:10.1007/s40267-017-0416-8 · Cited by 1
Mechanisms of resistance to lapatinib in HER2 positive breast cancer
McDermott, M. S. J. (2012) · Dublin City University Open Access Institutional Repository (Dublin City University) · Cited by 1
Mechanism‐Based Experimental Models for the Evaluation of BSEP Inhibition and DILI
Murphy, W. A., Saran, C., Honkakoski, P., & Brouwer, K. L. R. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch9 · Cited by 1
Mo, W. (2012) · IUScholarWorks (Indiana University) · doi:10.7912/c2/293
Al‐Dasooqi, N., Gibson, R. J., Bowen, J. M., & Keefe, D. M. K. (2012) · Wiley eBooks · doi:10.1002/9781119967309.ch3
Predicting drug-induced liver injury: safer patients or safer drugs?
Xu, J. J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511779053.006
Self-citationTargeting Organic Anion Transporting Polypeptides in Cancer to Improve Diagnostics and Therapy
Hays, A. L. (2012) · KU ScholarWorks (The University of Kansas)
Kenna, J. G., Stahl, S. H., & Noeske, T. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2013_30
Die Interaktion von ErbB2/Her2 mit Hitzeschockproteinen in Mammakarzinomzellen
Streller, F. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4867
Perioperative neutrophil immune function
Cain, D. J. (2017) · UCL Discovery (University College London)
Xu, J. J., & Hoffmaster, K. A. (2010) · Wiley eBooks · doi:10.1002/9780470915110.ch8
Self-citationReviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors
Han, J. M., & Gwak, H. S. (2019) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2019.29.4.223
Transporter, Drug Metabolism, and Drug‐Induced Liver Injury in Marketed Drugs
Chen, M., Ashby, K., & Wu, Y. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch2
Thakkar, N. (2015) · UKnowledge (University of Kentucky) · Cited by 1
El‐Kattan, A. F. (2017) · Wiley eBooks · doi:10.1002/9781118916926.ch3
Excretion of Drugs and Their Metabolites into the Bile
Gao, S., Etim, I., Sunsong, R., Ebuzoeme, C., Du, T., & Bui, D. (2023) · Wiley eBooks · doi:10.1002/9781119660699.ch14
Jackson, J. P., & Brouwer, K. R. (2025) · Applied In Vitro Toxicology · doi:10.1177/23321539251399331
Szabó, E., Telbisz, Á., Erdei, Z., Farkas, K., Homolya, L., Sarkadi, B., & Apáti, Á. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100157 · Cited by 1
BindingDB Entry 50018884: Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
BindingDB (2024) · UC San Diego · doi:10.7270/q2d50s68
Metadata
- Authors
- Feng, B., Xu, J. J., Bi, Y.-A., Mireles, R., Davidson, R., Duignan, D. B., Campbell, S., Kostrubsky, V. E., Dunn, M. C., Smith, A. R., & Wang, H. F.
- Affiliations
- Pfizer (United States) (US)
- Washington University in St. Louis (US)
- ORCID
- Feng, Bo
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-17
- Volume
- 108
- Issue
- 2
- Pages
- 492-500
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2144377055
- Cited by
- 80
- References
- 32
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 3 · 2013: 11 · 2012: 10
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- trastuzumab emtansine, HER2 tyrosine kinase inhibitor, hepatotoxicity, drug disposition, hepatic transporters, OATP1B1, MDR1, ABCG2, bile salt export pump, hepatocyte injury, drug-induced liver injury, mitochondrial toxicity, drug repurposing
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Multidrug Resistance-Associated Protein 2, Bile, Bile Acids and Salts, Calcium, Carrier Proteins, Cells, Cultured, Enzyme Inhibitors, Fluoresceins, Humans, Liver, Membrane Potentials, Neoplasm Proteins, Quinazolines, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, ATP Binding Cassette Transporter, Subfamily B, Member 1, Hepatocytes, Liver-Specific Organic Anion Transporter 1, Multidrug Resistance-Associated Proteins, ATP-Binding Cassette, Sub-Family C Proteins, Mitochondrial Membranes, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.